Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate 10x Genomics, Inc. before investing.

In this article, we go over a few key elements for understanding 10x Genomics, Inc.’s stock price such as:

• 10x Genomics, Inc.’s current stock price and volume
• Why 10x Genomics, Inc.’s stock price changed recently
• Upgrades and downgrades for TXG from analysts
• TXG’s stock price momentum as measured by its relative strength

About 10x Genomics, Inc. (TXG)

Before we jump into 10x Genomics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Want to learn more about 10x Genomics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about 10x Genomics, Inc..

10x Genomics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, 10x Genomics, Inc.’s stock price was $47.270.

10x Genomics, Inc. is down 4.37% from its previous closing price of $49.430.

During the last market session, 10x Genomics, Inc.’s stock traded between $46.250 and $50.340. Currently, there are approximately 128.29 million shares outstanding for 10x Genomics, Inc..

10x Genomics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

10x Genomics, Inc. Stock Price History

10x Genomics, Inc.’s (TXG) price is currently up 23.29% so far this month.

During the month of July, 10x Genomics, Inc.’s stock price has reached a high of $50.340 and a low of $35.120.

Over the last year, 10x Genomics, Inc. has hit prices as high as $49.840 and as low as $11.160. Year to date, 10x Genomics, Inc.’s stock is up 189.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused 10x Genomics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 30, 2026,, no analysts have changed their rating of 10x Genomics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate 10x Genomics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on 10x Genomics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

10x Genomics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about 10x Genomics, Inc. (TXG) by visiting AAII Stock Evaluator.

Relative Price Strength of 10x Genomics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, 10x Genomics, Inc. has a weighted four-quarter relative price strength of 55.95%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how 10x Genomics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

10x Genomics, Inc. Stock Price: Bottom Line

As of July 31, 2026, 10x Genomics, Inc.’s stock price is $47.270, which is down 4.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like 10x Genomics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.